Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Zhenyue Biotechnology Jiangsu Co., Ltd., established on 2015-12-16, Business scope includes biotechnology development,Technical Services,technology transfer,technical consulting,software development,data processing(without foundation,added value,Telecommunications business),Sales of computer software, hardware and auxiliary equipment,Chemical Products(Free of Hazardous Chemicals),Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that are restricted by the state to be operated by enterprises or prohibited from import and export),R&D of medical devices,production and sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

BC Cancer Agency provides healthcare services. The firm serves for hereditary cancer, indigenous cancer care, interpreters, and psychiatry. Its services include assessment and follow-up library, nutrition services, pain and symptom management, patient and family counselling, PET functional imaging, primary care, screening programs, and speech-language pathology. The company was founded on November 5, 1938 and is headquartered in Vancouver, Canada.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Atrys Health SA is a biomedical company, which engages in the research and development of diagnostic services. It offers medical treatment for oncology, radiology, cardiology, ophthalmology, and dermatology. The firm operates through the following segments: Telediagnosis, Diagnosis, Radiotherapy, Research & Development, and Smart & Big Data. The company was founded by Carlos Cordón-Cardó on January 4, 2007 and is headquartered in Barcelona, Spain.

Mohe Medical Technology (Shanghai) Co., Ltd., established on 2014-11-18, Business scope includes general items:Biochemical product technology research and development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Class I Medical Device Leasing;Class II Medical Device Leasing;Information Technology Consulting Services;Information security equipment sales;Retailing of computer software, hardware and auxiliary equipment;software sales;Import and export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Class III Medical Device Leasing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

PLTTECH engages in the R&D of single-cell precision research solutions. It is based on single-cell research in the field of precision medicine, and applies technological research and innovation to disease research and health management. The company aggregates the world's leading technologies such as single-cell detection, protein dynamic detection, and biological big data analysis, and provides excellent solutions for precision medicine and health management through extensive cooperation in the fields of medical scientific research, clinical diagnosis and treatment, and drug research and development. The company was founded in 2015 and is based in Hangzhou, China.

Guangzhou Fuda Cancer Hospital is a tertiary specialized cancer hospital which is affiliated with the Health Department of Guangdong Province in China. It was designated a national key clinical (cancer) hospital by the National Health and Family Planning Commission in 2011. The same year, Guangzhou Fuda Cancer Hospital was honored with National Trustworthy Private Hospital by the National Institute of Hospital Administration. In 2012, China Hospital Association rated Guangzhou Fuda Cancer Hospital as China Public Confidence Model Hospital. It was accredited by JCI in 2014.

Part of Innovent Biologics, Inc., Innovent Biologics (Suzhou) Co. Ltd. is a company headquartered in China. The firm manufactures pharmaceutical products.

Fun Biotechnology (Chengdu) Co., Ltd., established on 2013-03-13, The scope of business includes the research and development of bioengineering and biomedical engineering technology(The above scope does not include items restricted or prohibited by national laws and regulations,Those involved in licensing carry out business activities with relevant licenses).

Founded in December 2008, Shanghai Bohao Biotechnology Co., Ltd. (hereinafter referred to as "Bohao Biotechnology") is a high-tech enterprise focusing on scientific and technological services, disease and health detection services, and the development and production of molecular detection products. At the beginning of its establishment, Bohao Biotech, relying on Shanghai Biochip Co., Ltd./Shanghai National Engineering Research Center of Biochip, established a system technology service platform for scientific research and clinical research, providing one-stop scientific research services for high-throughput detection, bioinformatics analysis, marker screening and molecular detection verification, and gene function verification, as well as kit development One stop clinical service for production and testing of translational medicine. Bohao Biotech, together with its shareholding subsidiaries, Chongqing Bohao Medical Laboratory (a specialized subsidiary of clinical medical testing), Bohao Pharmaceutical (a specialized subsidiary of medical device business) and Xunberg Biotech (a specialized subsidiary of product research and development and GMP production), jointly opened a new chapter of "professional services make scientific discoveries, and industrial layout builds precision medicine". Since its establishment, the company has obtained a series of qualifications such as high-tech enterprises, enterprise research and development institutions in Pudong New Area, academician expert workstation, Shanghai R&D public service platform (responsible for the operation of "Shanghai High throughput Disease Markers Service Platform" and "Shanghai Gene Chip Professional Service Platform"), Shanghai service outsourcing public platform, Shanghai famous brand, Shanghai science and technology small giant enterprise, etc., and has medical institution practice license Business license of medical devices. In 2016, Bohao Biology was selected as the Demonstration Center for Gene Detection Technology Application of the National Development and Reform Commission, and jointly undertook the operation of the "Demonstration Center for Gene Detection of High Incidence Tumors and Hereditary Diseases" with Fudan University Affiliated Cancer Hospital, Shanghai Chest Hospital, Shanghai Children's Hospital, Shanghai Bioinformatics Research Center and other units. Bohao Biotech has established a standardized quality control system, passed the ISO9001: 2015 quality technology system certification, and made strict accusations on projects, samples, experimental processes, biological information analysis processes, data information management, confidentiality, etc. through 156 SOP documents with reference to the GLP-L standard. Bohao Bio adheres to the principle of "serving technological innovation and protecting human health!" Since its establishment, it has handled more than 300000 samples accumulatively, and assisted customers to publish more than 1600 SCI papers, with an average IF>5. The reliable quality has been recognized by domestic and international scientific research fields!

Wuxi Zhenhe Biotechnology Co., Ltd., established on 2014-11-17, Business scope includes licensed projects:Import and export agency(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;software development;Data processing and storage support services;Medical Research and Experimental Development;Retailing of computer software, hardware and auxiliary equipment;Communication equipment wholesale;Retailing of Class I Medical Devices;Wholesale of Class I Medical Devices;Wholesale of chemical products(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Based in China and led by U.S. diagnostic industry veterans, Shuwen Biotech is engaged in licensing and developing innovative diagnostic products and services for disease prevention, diagnosis and personalized medicine, and strives to offer in China a comprehensive menu of the most innovative diagnostic products and services for improved disease prediction, screening, diagnosis, prognosis and treatment.